BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37226019)

  • 1. The relationship between anxiety and vaginal-related sexual health in postmenopausal breast cancer survivors on aromatase inhibitors therapies: a cross sectional study.
    Bryl K; Chimonas S; Li X; Li SQ; Mao JJ
    Breast Cancer Res Treat; 2023 Jul; 200(2):257-264. PubMed ID: 37226019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial.
    Mension E; Alonso I; Anglès-Acedo S; Ros C; Otero J; Villarino Á; Farré R; Saco A; Vega N; Castrejón N; Ordi J; Rakislova N; Tortajada M; Matas I; Gómez S; Ribera L; Castelo-Branco C
    JAMA Netw Open; 2023 Feb; 6(2):e2255697. PubMed ID: 36763359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy.
    Advani P; Brewster AM; Baum GP; Schover LR
    J Cancer Surviv; 2017 Aug; 11(4):477-485. PubMed ID: 28229275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
    Buchholz S; Mögele M; Lintermans A; Bellen G; Prasauskas V; Ortmann O; Grob P; Neven P; Donders G
    Climacteric; 2015 Apr; 18(2):252-9. PubMed ID: 25427450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
    Desai K; Mao JJ; Su I; Demichele A; Li Q; Xie SX; Gehrman PR
    Support Care Cancer; 2013 Jan; 21(1):43-51. PubMed ID: 22584732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual function after breast cancer.
    Panjari M; Bell RJ; Davis SR
    J Sex Med; 2011 Jan; 8(1):294-302. PubMed ID: 21199377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
    Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
    Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
    Custódio IDD; Nunes FSM; Lima MTM; de Carvalho KP; Alves DS; Chiaretto JF; Canto PPL; Paiva CE; de Paiva Maia YC
    BMC Cancer; 2022 Aug; 22(1):860. PubMed ID: 35933326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
    Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
    Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey.
    Smedsland SK; Vandraas KF; Bøhn SK; Dahl AA; Kiserud CE; Brekke M; Falk RS; Reinertsen KV
    Breast Cancer Res Treat; 2022 May; 193(1):139-149. PubMed ID: 35226237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.
    Kuehn R; Casaubon J; Raker C; Edmonson D; Stuckey A; Gass J
    Ann Surg Oncol; 2019 Oct; 26(10):3159-3165. PubMed ID: 31342358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
    JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
    Schover LR; Baum GP; Fuson LA; Brewster A; Melhem-Bertrandt A
    J Sex Med; 2014 Dec; 11(12):3102-11. PubMed ID: 25141792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
    de Paulo TRS; Winters-Stone KM; Viezel J; Rossi FE; Aro BL; Trindade ACAC; Codogno JS; Freitas Junior IF
    Disabil Rehabil; 2019 Sep; 41(18):2175-2182. PubMed ID: 29644889
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
    Bailey S; Mhango G; Lin JJ
    Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
    Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
    Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors.
    Carter J; Baser RE; Goldfrank DJ; Seidel B; Milli L; Stabile C; Canty J; Saban S; Goldfarb S; Dickler MN; Gardner GJ; Jewell EL; Sonoda Y; Kollmeier MA; Alektiar KM
    Support Care Cancer; 2021 Jan; 29(1):311-322. PubMed ID: 32358778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.